Ipca Laboratories gained 0.63% to Rs 600 at 15:17 IST on BSE on receiving US Food and Drug Administration approval for propranolol hydrochloride tablets.
Meanwhile, the BSE Sensex was down 415.99 points, or 2.61%, to 15,546.57.
On BSE, 4,888 shares were traded in the counter. The scrip had an average daily volume of 9,737 shares in the past one quarter.
The stock hit a high of Rs 614 and a low of Rs 595 so far during the day. The stock had a 52-week high of Rs 794 on 4 July 2007 and the stock hit a 52-week low of Rs 451 on 24 March 2008.
The mid-cap company had outperformed the market over the past one month till 3 June 2008, declining 5.33% compared to the Sensex’s decline of 8.74%. It had also outperformed the market in the past one quarter, rising 0.95% compared to Sensex’s decline of 3.50%.
The company’s current equity is Rs 25.09 crore. Face value per share is Rs 10.
The current price of Rs 600 discounts its Q4 March 2008 annualised EPS of Rs 36.09, by a PE multiple of 16.53.
Ipca Laboratories in an announcement made during trading hours today, 4 June 2008 said that the USFDA approval is for tablets of 10, 20, 40, 60 & 80 milligrams strengths. Total annual sales for propranolol hydrochloride tablets in US market were $24.1 million in December 2007.
Ipca Laboratories’ net profit fell 18.11% to Rs 22.64 crore on 15.15% rise in total income to Rs 255.10 crore in Q4 March 2008 over Q4 March 2007.
The company manufactures and distributes drugs and pharmaceuticals. The products of the group include tablets, capsules, basic drugs, orals, liquids and injectables. The group operates in Russia, Kazakhstan, Ukraine, Belarus, Uzbekistan and India.
Meanwhile, the BSE Sensex was down 415.99 points, or 2.61%, to 15,546.57.
On BSE, 4,888 shares were traded in the counter. The scrip had an average daily volume of 9,737 shares in the past one quarter.
The stock hit a high of Rs 614 and a low of Rs 595 so far during the day. The stock had a 52-week high of Rs 794 on 4 July 2007 and the stock hit a 52-week low of Rs 451 on 24 March 2008.
The mid-cap company had outperformed the market over the past one month till 3 June 2008, declining 5.33% compared to the Sensex’s decline of 8.74%. It had also outperformed the market in the past one quarter, rising 0.95% compared to Sensex’s decline of 3.50%.
The company’s current equity is Rs 25.09 crore. Face value per share is Rs 10.
The current price of Rs 600 discounts its Q4 March 2008 annualised EPS of Rs 36.09, by a PE multiple of 16.53.
Ipca Laboratories in an announcement made during trading hours today, 4 June 2008 said that the USFDA approval is for tablets of 10, 20, 40, 60 & 80 milligrams strengths. Total annual sales for propranolol hydrochloride tablets in US market were $24.1 million in December 2007.
Ipca Laboratories’ net profit fell 18.11% to Rs 22.64 crore on 15.15% rise in total income to Rs 255.10 crore in Q4 March 2008 over Q4 March 2007.
The company manufactures and distributes drugs and pharmaceuticals. The products of the group include tablets, capsules, basic drugs, orals, liquids and injectables. The group operates in Russia, Kazakhstan, Ukraine, Belarus, Uzbekistan and India.
0 comments:
Post a Comment